K
Koen van Besien
Researcher at Cornell University
Publications - 350
Citations - 11857
Koen van Besien is an academic researcher from Cornell University. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 49, co-authored 328 publications receiving 10855 citations. Previous affiliations of Koen van Besien include City of Hope National Medical Center & University of Texas MD Anderson Cancer Center.
Papers
More filters
Journal ArticleDOI
Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy
Sergio Giralt,Elihu H. Estey,Maher Albitar,Koen van Besien,Gabriela Rondon,Paolo Anderlini,Susan O'Brien,Issa F. Khouri,James Gajewski,Rakesh Mehra,David F. Claxton,Borje S. Andersson,Miloslav Beran,Donna Przepiorka,Charles Koller,Steve Kornblau,Martin Korbling,Michael J. Keating,Hagop M. Kantarjian,Richard E. Champlin +19 more
TL;DR: It is concluded that purine analog-containing nonmyeloablative regimens allow engraftment of HLA-compatible hematopoietic progenitor cells and warrants further study in patients with leukemia who are ineligible for conventional transplantation with myeloablatives either because of age or concurrent medical conditions.
Journal ArticleDOI
Lenalidomide after stem-cell transplantation for multiple myeloma
Philip L. McCarthy,Kouros Owzar,Craig C. Hofmeister,David D. Hurd,Hani Hassoun,Paul G. Richardson,Sergio Giralt,Edward A. Stadtmauer,Daniel J. Weisdorf,Ravi Vij,Jan S. Moreb,Natalie S. Callander,Koen van Besien,Teresa Gentile,Luis Isola,Richard T. Maziarz,Don A. Gabriel,Asad Bashey,Heather Landau,Thomas G. Martin,Muzaffar H. Qazilbash,Denise Levitan,Brian McClune,Robert L. Schlossman,Vera Hars,John Postiglione,Chen Jiang,Elizabeth Bennett,Susan Barry,Linda Bressler,Michael Kelly,Michele Seiler,Cara A. Rosenbaum,Parameswaran Hari,Marcelo C. Pasquini,Mary M. Horowitz,Thomas C. Shea,Steven M. Devine,Kenneth C. Anderson,Charles A. Linker +39 more
TL;DR: Lenalidomide maintenance therapy, initiated at day 100 after hematopoietic stem-cell transplantation, was associated with more toxicity and second cancers but a significantly longer time to disease progression and significantly improved overall survival among patients with myeloma.
Journal ArticleDOI
Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma.
Koen van Besien,Fausto R. Loberiza,Ruta Bajorunaite,James O. Armitage,Asad Bashey,Linda J. Burns,Cesar O. Freytes,John Gibson,Mary M. Horowitz,David J. Inwards,David I. Marks,Rodrigo Martino,Richard T. Maziarz,Arturo Molina,Santiago Pavlovsky,Andrew L. Pecora,Harry C. Schouten,Thomas C. Shea,Hillard M. Lazarus,J. Douglas Rizzo,Julie M. Vose +20 more
TL;DR: It is concluded that both allogeneic and autologous transplantation can induce durable remissions and there may be a benefit to graft purging in autologus transplantation.
Journal ArticleDOI
A multicenter prospective phase 2 randomized study of extracorporeal photopheresis for treatment of chronic graft-versus-host disease
Mary E.D. Flowers,Jane F. Apperley,Koen van Besien,Ahmet H. Elmaagacli,Andrew Grigg,Vijay Reddy,Andrea Bacigalupo,Hans-Jochem Kolb,Luis Fernando Bouzas,Mauricette Michallet,H. Miles Prince,Robert Knobler,Dennis Parenti,Jose Gallo,Hildegard T. Greinix +14 more
TL;DR: It is suggested that ECP may have a steroid-sparing effect in the treatment of cGVHD and was generally well tolerated.
Journal ArticleDOI
Risk Factors, Treatment, and Outcome of Central Nervous System Recurrence in Adults With Intermediate-Grade and Immunoblastic Lymphoma
Koen van Besien,Chul S. Ha,Sandy Murphy,Peter McLaughlin,Alma Rodriguez,Kamal Amin,Arthur D. Forman,Jorge E. Romaguera,Fredrick B. Hagemeister,Anas Younes,Carlos Bachier,Andreas H. Sarris,Kathleen S. Sobocinski,James D. Cox,Fernando Cabanillas +14 more
TL;DR: Serum LDH and involvement of more than one extranodal site are independent risk factors for CNS recurrence in patients with large-cell lymphoma and the presence of both risk factors identifies a patient group at high risk for central nervous system recurrence.